Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Robotic magnetic catheter takes aim at stubborn heart rhythms in adults born with heart defects

NCT ID NCT07812818

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

Adults with congenital heart disease often develop supraventricular tachycardia, a fast or irregular heartbeat that can be hard to treat because of unusual heart anatomy or prior surgeries. This study follows 40 adults who have a cardiac ablation procedure using the MAGiC ablation catheter, which a robotic magnetic system steers through the heart. Researchers track whether the procedure stops the targeted arrhythmia right away and whether it stays gone for six months, while recording any device or procedure related safety problems. Participants visit their doctor at one week, one month, and six months after the procedure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cardiac ablation using the MAGiC ablation catheter guided by a robotic magnetic system
What this could lead to
If it works, doctors could have a clearer picture of whether robotic magnetic ablation reliably controls supraventricular tachycardia in adults whose congenital heart disease makes standard catheter access difficult.
What could go wrong
This is a small post-approval study of 40 people, so it may not capture rare complications or show how the approach performs across the wide range of congenital heart defects. Ablation carries risks of bleeding, vessel injury, or heart rhythm problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Any patients requiring an ablation procrdure for the treatment of SVT with CHD where there is limited vascular ascess or difficult to access the target cardiac chamber

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult (aged 18 or older at time of consent). * Clinically indicated for catheter ablation of a supraventricular tachycardia (macroreentrant atrial tachycardia, focal atrial tachycardia, atrioventricular nodal reentrant tachycardia, and atrioventricular reentrant tachycardia) * History of congenital heart disease with anatomic abnormalities and/or previous surgical interventions and/or previous surgical interventions that limit vascular or target chamber access by conventional manual catheter navigation. * Willing and capable of attending scheduled follow up visits for the study duration = Willing and able to provide informed consent. Exclusion Criteria: * Atrial fibrillation is the target arrhythmia for the catheter ablation. * Unable to be safely exposed to the level of magnetic fields used for Robotic Magnetic Navigation * A history of sensitivity to foreign objects (gold, platinum/iridium, Pebax materials) or extreme allergies. * Acute illness or active systemic infection. * Histological or anatomical abnormalities that may lead to post-operative complications including diminished resistance to infection. * Hemodynamic instability (to an extent that would make an interventional procedure high risk). * Presence of intracardiac thrombus. * Where MAGiC would need to cross a prosthetic valve. * Where MAGiC would need to be used in the coronary arteries. * Unable to receive heparin or an acceptable alternative to achieve adequate anticoagulation. * Acute myocardial infarct (within the previous 30 days). * Unstable angina at the time of enrollment. * History of embolism (cerebrovascular accident, transient ischemic attack, systemic embolism) in the previous 30 days. * Previous cardiac ablation within the last 30 days. * Inaccessible for follow-up visits for 6 months post ablation. * Significant uncontrolled or unstable medical problems which, in the opinion of the Investigator, would preclude enrollment in and completion of the study. * Any reason or condition that, in the judgement of the investigator, makes the subject ineligible for the investigation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Congenital heart disease (CHD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

congenital heart disease Tachycardia, Supraventricular

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.